-
公开(公告)号：EP4417624A2
公开(公告)日：2024-08-21
申请号：EP24172994.6
申请日：2014-01-31
发明人： DAVIS, Samuel , SMITH, Eric , PATEL, Supriya , RAFIQUE, Ashique
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , C07K2317/3120130101 , C07K16/46 , C07K2317/2420130101 , C07K2317/5220130101 , C07K2317/7120130101 , C07K2317/73220130101 , C07K2317/73420130101 , C07K2317/9420130101 , C07K16/2809 , A61P43/00
摘要： Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
-
公开(公告)号：EP3221359A1
公开(公告)日：2017-09-27
申请号：EP15801637.8
申请日：2015-11-17
发明人： SMITH, Eric , DAVIS, Samuel , VARGHESE, Bindu , KIRSHNER, Jessica R. , THURSTON, Gavin , LOWY, Israel , BROWNSTEIN, Carrie
摘要： The present invention relates to a method (dosage regimen) for administering a CD3×CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3×CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3×CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose, the second dose, and any subsequent doses are also part of the present invention.
摘要翻译： 本发明涉及用于向人类患者施用CD3xCD20双特异性抗体的方法（剂量方案），其包括（a）以特定剂量施用第一剂量的所述抗体; （b）在一段时间之后施用第二剂量的所述抗体，其中所述第二剂量超过所述第一剂量。 本发明的方法（以及同样的本发明的剂量方案）也适合于治疗人类患者的B细胞（CD20阳性）癌症或者用于改善和/或预防由周期性或持续给药介导的医学病症 的CD3 x CD20双特异性抗体给人类患者。 本发明还涉及CD3 x CD20双特异性抗体用于制备待用于如前述权利要求中任一项所定义的方法或治疗方案的药物组合物的用途。 包含第一剂量，第二剂量和任何后续剂量的药物包装或试剂盒也是本发明的一部分。
-
公开(公告)号：EP2970437A1
公开(公告)日：2016-01-20
申请号：EP14722432.3
申请日：2014-03-13
发明人： BABB, Robert , MCWHIRTER, John , MACDONALD, Lynn , STEVENS, Sean , DAVIS, Samuel , BUCKLER, David R. , MEAGHER, Karolina A. , MURPHY, Andrew J. , LEVENKOVA, Natasha
IPC分类号： C07K16/00 , C07K16/46 , A01K67/027 , C12N15/85
CPC分类号： A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2217/15 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K16/28 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C12N15/8509
摘要： A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
-
公开(公告)号：EP2951207A1
公开(公告)日：2015-12-09
申请号：EP14706169.1
申请日：2014-01-31
发明人： DAVIS, Samuel , SMITH, Eric , PATEL,Supriya , RAFIQUE, Ashique
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , C07K16/2887 , C07K16/2896 , C07K16/46 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/53 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94 , C12N15/85
摘要： Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
-
公开(公告)号：EP2701499A2
公开(公告)日：2014-03-05
申请号：EP12717033.0
申请日：2012-04-24
发明人： MCWHIRTER, John , MACDONALD, Lynn , STEVENS, Sean , DAVIS, Samuel , BUCKLER, David, R. , HOSIAWA, Karolina, A. , MURPHY, Andrew, J.
IPC分类号： A01K67/027
CPC分类号： A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2217/15 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/515 , C07K2317/76 , C07K2319/30 , C12N15/8509 , C12N2800/204
摘要： A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.
-
公开(公告)号：EP0915974B1
公开(公告)日：2004-03-17
申请号：EP97937086.3
申请日：1997-08-01
IPC分类号： C12N15/12 , C07K14/515 , C07K14/71 , C07K16/22 , C12N15/62 , C07K19/00 , A61K38/17 , A61K38/18 , A61K39/395 , A61K49/00 , A61K51/08
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/30 , A01K2267/01 , A01K2267/03 , A01K2267/0331 , A01K2267/0375 , A01K2267/0381 , A61K38/00 , C07K14/515 , C07K14/71 , C07K2319/00 , C07K2319/02
摘要： The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
-
公开(公告)号：EP4355427A1
公开(公告)日：2024-04-24
申请号：EP22736464.3
申请日：2022-06-13
发明人： LIN, Chia-Yang , WU, Jiaxi , BLOCH, Nicolin , ZHANG, Tong , DAVIS, Samuel , SMITH, Eric , ULLMAN, Erica
-
公开(公告)号：EP4010371A1
公开(公告)日：2022-06-15
申请号：EP20760702.9
申请日：2020-08-07
发明人： ZHANG, Tong , PYLES, Erica , ROSCONI, Michael , LIU, Nina , PATEL, Supriya , SMITH, Eric , MURPHY, Andrew , LIN, Chiayang , DAVIS, Samuel
-
公开(公告)号：EP3848395A1
公开(公告)日：2021-07-14
申请号：EP21151864.2
申请日：2015-03-18
IPC分类号： C07K16/28 , A61K39/395
摘要： The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcy receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcy receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
-
公开(公告)号：EP2989893B1
公开(公告)日：2019-06-19
申请号：EP15186515.1
申请日：2012-04-24
发明人： MCWHIRTER, John , MACDONALD, Lynn , STEVENS, Sean , DAVIS, Samuel , BUCKLER, David R. , HOSIAWA, Karolina A. , MURPHY, Andrew J.
IPC分类号： A01K67/027 , C07K16/00 , C07K16/46 , C12N15/85
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.028 秒)
